Loading...
•
Jun 30, 2025
Immunocore Q2 2025 Earnings Report
Immunocore reported strong second quarter 2025 financial results, driven by significant growth in KIMMTRAK net product sales and continued progress in its clinical pipeline.
Key Takeaways
Immunocore announced robust second quarter 2025 financial results, with KIMMTRAK net product sales reaching $98.0 million, a 30% year-over-year increase. The company reported a net loss of $10.3 million and a loss per share of $0.20, showing an improvement compared to the same period last year. Significant progress was made in advancing its Phase 3 trials for TEBE-AM and PRISM-MEL-301, alongside the expansion of KIMMTRAK's global reach.
KIMMTRAK net product sales reached $98.0 million in Q2 2025, marking a 30% year-over-year increase.
The company's net loss improved to $10.3 million in Q2 2025, down from $11.6 million in Q2 2024.
Research and development expenses increased to $69.0 million, reflecting significant investment in advancing clinical trials and autoimmune programs.
Cash, cash equivalents, and marketable securities stood at $882.8 million as of June 30, 2025, indicating a strong liquidity position.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Immunocore expects continued global expansion for KIMMTRAK, progression of its Phase 3 clinical trials, and anticipates filing clinical trial applications for its autoimmune candidates. The company also expects to pay approximately $65 million in sales-related rebate accruals in the second half of 2025.
Positive Outlook
- Continued global expansion of KIMMTRAK in metastatic uveal melanoma.
- Potential expansion of KIMMTRAK into 2L+ advanced cutaneous melanoma.
- Potential expansion of KIMMTRAK into adjuvant uveal melanoma.
- Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026.
- Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025.
Challenges Ahead
- Expected payment of approximately $65 million in sales-related rebate accruals in 2H 2025.
- Risks associated with obtaining and maintaining regulatory approval for product candidates.
- Potential for delays in current or planned clinical trials due to patient enrollment or other factors.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...